

# 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/59B86BA087BAEN.html>

Date: May 2022

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: 59B86BA087BAEN

## Abstracts

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

The report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Respiratory which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Anxiety Disorders, Autism, Depression, Neuropathic Pain (Neuralgia), Psychiatric Disorders, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Crohn's Disease (Regional Enteritis), Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Ulcerative Colitis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects

The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

HTR7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -  
Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -  
Companies Involved in Therapeutics Development

Adamed Pharma SA

Avineuro Pharmaceuticals Inc

Celon Pharma SA

Core One Labs Inc

Daya Drug Discoveries Inc

H. Lundbeck AS

Johnson & Johnson

LB Pharmaceuticals Inc

Praeventix LLC

Reviva Pharmaceuticals Inc

Sumitomo Pharma Co Ltd

Sunovion Pharmaceuticals Inc

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -  
Drug Profiles

5HT7 Agonist - Drug Profile

Product Description

Mechanism Of Action

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action  
ADN-3662 - Drug Profile  
Product Description  
Mechanism Of Action  
amisulpride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AVN-101 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
brilaroxazine - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
DDD-028 - Drug Profile  
Product Description  
Mechanism Of Action  
dimethyltryptamine - Drug Profile  
Product Description  
Mechanism Of Action  
JNJ-18038683 - Drug Profile  
Product Description  
Mechanism Of Action  
LB-102 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
LB-102 LA - Drug Profile  
Product Description  
Mechanism Of Action  
LB-104 - Drug Profile  
Product Description  
Mechanism Of Action  
lurasidone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events

Small Molecules to Antagonize 5 HT7 Receptors for Crohn's Disease and Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

vortioxetine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

History of Events

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones

Featured News & Press Releases

May 03, 2022: Reviva Pharmaceuticals announces update on RECOVER, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia

Apr 26, 2022: Reviva Pharmaceuticals to host key opinion leader webinar on brilaroxazine for schizophrenia and Other neuropsychiatric disorders

Apr 11, 2022: Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study

Mar 03, 2022: Core One Labs announces successful proof-of-concept for biosynthetic N-methyltryptamine (NMT)

Feb 10, 2022: Core One Labs expects imminent breakthrough to produce NMT, Precursor to DMT

Feb 09, 2022: Sunovion and Otsuka initiate Phase 3 clinical development of non-racemic amisulpride for the treatment of people with bipolar depression

Feb 01, 2022: Reviva Pharmaceuticals announces first patients dosed in pivotal phase 3 study and long-term safety trial evaluating Brilaroxazine for the treatment of schizophrenia

Jan 10, 2022: Reviva Pharmaceuticals Holdings receives FDA may proceed letter for pivotal phase 3 clinical trial and long-term safety trial evaluating Brilaroxazine for the treatment of Schizophrenia

Dec 07, 2021: LB announces presentation of full results of dopamine receptor occupancy study of LB-102 at the 2021 ACNP conference

Oct 04, 2021: LB Pharmaceuticals presents results of dopamine receptor occupancy studies of LB-102 at ECNP conference

Oct 01, 2021: U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent

May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder

May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021

Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia

Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by Adamed Pharma SA, 2022  
Pipeline by Avineuro Pharmaceuticals Inc, 2022  
Pipeline by Celon Pharma SA, 2022  
Pipeline by Core One Labs Inc, 2022  
Pipeline by Daya Drug Discoveries Inc, 2022  
Pipeline by H. Lundbeck AS, 2022  
Pipeline by Johnson & Johnson, 2022  
Pipeline by LB Pharmaceuticals Inc, 2022  
Pipeline by Praeventix LLC, 2022  
Pipeline by Reviva Pharmaceuticals Inc, 2022  
Pipeline by Sumitomo Pharma Co Ltd, 2022  
Pipeline by Sunovion Pharmaceuticals Inc, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

## I would like to order

Product name: 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)  
Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule  
Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/59B86BA087BAEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/59B86BA087BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970